{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.7","upperLimit":"42.8","value":"25.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"PFS was defined as the time from the brexucabtagene autoleucel infusion date to the date of PD or death from any cause. PD: a score 4 (uptake moderately \\> liver) or 5 (uptake markedly \\>liver and/or new lesions) with an increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment; new FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation); new or recurrent FDG-avid foci in bone marrow. PFS was determined using the KM estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\\^2/day and cyclophosphamide 500 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.","id":"OG000","title":"Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel"}],"paramType":"MEDIAN","populationDescription":"Participants from the mITT Analysis Set in Cohort 1 were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 7.8 years","title":"Progression Free Survival (PFS) in Cohort 1 as Per Investigator Response.","type":"SECONDARY","unitOfMeasure":"months"}